MANTA Brings Glimmer Of Good News To Galapagos

Promising Early Filgotinib Data Boosts Stock

After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.

manta
Manta keeps hope of filgotinib IBD approvals afloat • Source: Shutterstock

More from Clinical Trials

More from R&D